266 related articles for article (PubMed ID: 25587962)
1. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Matsuoka A; Maeda O; Ando Y
N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962
[No Abstract] [Full Text] [Related]
2. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Haines IE
N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
[No Abstract] [Full Text] [Related]
3. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Cremolini C; Loupakis F; Falcone A
N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
[No Abstract] [Full Text] [Related]
4. Gastrointestinal cancer: FOLFOXIRI-improving outcomes of metastatic colorectal cancer.
Errico A
Nat Rev Clin Oncol; 2014 Dec; 11(12):684. PubMed ID: 25384949
[No Abstract] [Full Text] [Related]
5. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
6. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in colorectal cancer.
Sharieff W
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
[No Abstract] [Full Text] [Related]
8. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
9. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F; Cunningham D
Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
[No Abstract] [Full Text] [Related]
11. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
12. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
13. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Lindsay CR; Roxburgh P; Graham J
Future Oncol; 2013 Jun; 9(6):825-9. PubMed ID: 23718303
[TBL] [Abstract][Full Text] [Related]
14. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Kawakami H; Satoh T; Nakagawa K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
[No Abstract] [Full Text] [Related]
15. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
[No Abstract] [Full Text] [Related]
16. Second-line therapy for metastatic colorectal cancer.
Price TJ
Lancet Oncol; 2015 May; 16(5):476-7. PubMed ID: 25877856
[No Abstract] [Full Text] [Related]
17. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Copur MS; Norvell M; Obermiller A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033
[No Abstract] [Full Text] [Related]
19. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
20. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
Sunakawa Y; Schirripa M; Lenz HJ
Crit Rev Oncol Hematol; 2016 Apr; 100():117-26. PubMed ID: 26850575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
